Calithera Biosciences (NASDAQ:CALA) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Rating) in a research note released on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Calithera Biosciences Trading Up 4.3 %

Shares of CALA stock opened at $0.37 on Monday. The company’s 50-day moving average price is $0.07 and its 200-day moving average price is $0.83. The stock has a market cap of $1.78 million, a price-to-earnings ratio of -0.01 and a beta of 1.18. Calithera Biosciences has a twelve month low of $0.01 and a twelve month high of $5.10.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CALA. Alyeska Investment Group L.P. acquired a new position in Calithera Biosciences in the first quarter valued at about $404,000. Affinity Asset Advisors LLC purchased a new stake in Calithera Biosciences during the first quarter worth about $404,000. Renaissance Technologies LLC increased its stake in Calithera Biosciences by 36.5% during the first quarter. Renaissance Technologies LLC now owns 1,853,500 shares of the biotechnology company’s stock worth $749,000 after purchasing an additional 496,100 shares during the period. Goldman Sachs Group Inc. increased its stake in Calithera Biosciences by 143.2% during the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 72,865 shares during the period. Finally, Vanguard Group Inc. increased its stake in Calithera Biosciences by 23.4% during the third quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company’s stock worth $415,000 after purchasing an additional 26,800 shares during the period. Institutional investors and hedge funds own 33.73% of the company’s stock.

Calithera Biosciences Company Profile

(Get Rating)

Calithera Biosciences, Inc is a clinical stage precision oncology biopharmaceutical company, which engages in developing targeted therapies to redefine treatment for biomarker-specific patient populations. It also focuses on researching small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic.